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Abstract Autoimmune chronic active hepatitis (AI-CAH) is a 
feared component of autoimmune polyendocrine syndrome type I 
(APS I). In this study, immunoreactivity was assessed in sera 
from eight APS I patients, of whom three had AI-CAH, in an 
attempt to identify hepatic autoantigens. We performed indirect 
immunofluorescence staining of human and rat liver sections, 
Western blots on subcellular fractions of human and rat liver, 
immunoprecipitations of labelled aromatic L-amino acid de-
carboxylase (AADC) and cytochrome P450IA2 (CYP IA2) 
expressed by an in vitro transcription and translation system and 
studies of enzymatic activity. Autoantibodies against AADC 
were present in sera from all eight APS I patients, while 
immunoreactivity against CYP IA2 was only found in sera from 
the three APS I patients with AI-CAH. Enzymatic activity of 
CYP IA2 was inhibited by sera from APS I patients with AI-
CAH but not by control sera. Our results show that CYP IA2 
and AADC constitute hepatic autoantigens in patients with APS 
I and that immunoreactivity against CYP IA2 is associated with 
the presence of AI-CAH. 
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1. Introduction 
Autoimmune chronic active hepatitis (AI-CAH) occurs in 
11-12% of patients with autoimmune polyendocrine syndrome 
type I (APS I) [1-3]. Autoantibodies are important diagnostic 
markers for AI-CAH and at least three subgroups can be 
distinguished serologically [4,5]. One of these subgroups, AI-
CAH type 2, is associated with specific liver-kidney micro-
somal (LKM) antibodies. Target autoantigens for LKM anti-
bodies have been identified as cytochrome P450 enzymes, the 
most common being cytochrome P450 IID6 (CYP IID6) [6]. 
LKM antibodies against cytochrome P450 IIC9 are associated 
with drug-induced hepatitis [7]. In a case of AI-CAH associ-
ated with alopecia, vitiligo and nail dystrophy, LKM anti-
bodies reacting against cytochrome P4501A2 (CYP IA2) 
were found [8,9]. Although not diagnosed as having APS I, 
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the child seems to have this syndrome on the clinical descrip-
tion. CYPI A2 is a liver-specific enzyme, located in perivenous 
hepatocytes [10], and is involved in drug metabolism such as 
O-de-ethylation of phenacetin [11,12]. 
APS I, also called autoimmune polyendocrinopathy-candi-
diasis-ectodermal dystrophy (APECED), is characterised by 
mucocutaneous candidiasis, organ-specific autoimmunity and 
ectodermal manifestations [1,2]. It is inherited in an autoso-
mal recessive manner. Both cellular and humoral autoimmu-
nity are probably involved in the pathogenesis of this disor-
der, and the underlying genetic defect, the nature of which is 
unknown, has been mapped to chromosome 21 [13]. Common 
endocrine features of this syndrome are hypoparathyroidism, 
adrenocortical insufficiency, gonadal failure and, more rarely, 
diabetes mellitus, hypothyroidism and parietal cell atrophy. 
Additional non-endocrine manifestations are mucocutaneous 
candidiasis, nail dystrophy, alopecia, vitiligo, intestinal mal-
absorption and, one of the most serious, autoimmune chronic 
active hepatitis [1,2]. APS I patients display autoantibodies 
against several of the organs affected and some of these auto-
antigens have been identified. The major autoantigen in the 
adrenal cortex and gonads is P450scc (side-chain cleavage en-
zyme) [14,15]. In the pancreatic (3-cells glutamic acid decar-
boxylase (GAD) [16,17] and aromatic L-amino acid decarbox-
ylase (AADC) [18] have been identified as autoantigens. 
AADC is an enzyme known to be involved in the biosynthesis 
of catecholamine and indolamine neurotransmitters [19]. Be-
sides being present in nervous tissue, AADC is found in large 
amounts in neuroendocrine cells, the liver and the kidney [20]. 
Its function in the liver is largely unknown. 
Identification of the liver autoantigens in APS I would pro-
vide a basis to develop antibody assays to monitor APS I 
patients with AI-CAH or at risk of developing this disease. 
Using immunofluorescence staining of tissue sections, Western 
blots of subcellular fractions and immunoprecipitation assays 
based on radioactively labelled recombinant proteins, we here 
describe two liver enzymes, CYP IA2 and AADC, recognised 
by autoantibodies in APS I patients. 
2. Materials and methods 
2.1. Subjects 
Sera from eight patients with APS I were investigated. All patients 
have previously been reported on [3,14,15]. Chronic active hepatitis 
(CAH), as verified by liver biopsy, was present in three of these pa-
tients. At the time of our investigations all three patients were having 
immunosuppressive treatment in the form of azathioprine (25 mg/ 
day), and two of the patients were also receiving synthetic steroids 
(patient. #1: prednisolone 10 mg/day and cortisone 25 mg/day; pa-
tient #3: prednisone 5 mg/2 days and cortisone 5 mg/2 days). Further 
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clinical details are given in Table 1. Sera from 10 healthy blood do-
nors were used as controls. 
2.2. Antibodies 
Rabbit anti-rat CYP IA2 and CYP IID6 peptide antibodies were 
kindly provided by Professor A. Rane. A specific rabbit serum against 
AADC was a kind gift from Dr. Krieger and was also purchased from 
Biogenesis (Poole, Dorset, UK). Fluorescein-conjugated and alkaline 
phosphatase-conjugated species-specific anti-IgG immunoglobulins 
were obtained from Dakopatts (Glostrup, Denmark). 
2.3. Indirect immunofluorescence 
Indirect immunofluorescence staining (IF) of unfixed frozen sec-
tions of human and rat liver was performed as previously described 
[21]. All sections were scored positive or negative according to the 
presence of cytoplasmic IF staining in a blinded fashion by two in-
dependent investigators. Randomly selected blood donors and a slide 
incubated with PBS and secondary antibody were used as negative 
controls, while specific antisera against CYP IA2 and AADC were 
used as positive controls. 
Fig. 1. Indirect immunofluorescence analysis of rat liver sections using specific antisera and patient sera. A: Anti-CYP IA2; B: APS I patient 
#3 ; C: healthy control. 
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Fig. 1 (continued). 
performed as described. Samples of antigen fractions were quantified 
2.4. Preparation of antigen, SDS-P'AGE and Western blot for their total protein concentration using the Ms-cinchonic acid 
Human liver was obtained from an healthy organ donor. The tissue (BCA) protein assay method (Pierce Chemical Company, Rockford, 
was removed within 30 min of death and immediately put in liquid IL). 
nitrogen. Human and rat liver homogenates were prepared by homo-
genisation in a buffer containing 10 mM Tris-HCl, pH 7.4, 0.25 M 2.5. Synthesis of cytochrome P450 IA2 and AADC by in vitro 
sucrose, 1 mM EDTA and 1 mM PMSF. Cytosol and microsome transcription and translation 
fractions were prepared by differential centrifugation as described The full-length CYP IA2 cDNA clone (American Type Culture 
by Axen et al. [22]. SDS-PAGE [23] and Western blots [14] were Collection, Rockville, MD) and the full-length rat cDNA clone encod-
Table 1 
Clinical characteristics and experimental results in the eight APS I patients studied 
Patients 
1 2 3 4 5 6 7 8 
Endocrine 
Adrenal insufficiency + + + + — + + + 
Hypoparathyroidism — + — + + + + + 
Gonadal insufficiency — + _ _ _ _ + _ 
Hypothyroidism — — + — — + — — 
Non-endocrine 
Candidiasis + + + + + + + + 
Hepatitis + - + - - - - + 
Alopecia + + — — — + — — 
Vitiligo _ + _ _ _ + _ _ 
Malabsorption — — + + + — + + 
Investigations 
Liver IFa + + + + NT + + + 
Western blot 
CYP IA2 + - + - - - - + 
AADC - + + + + + + + 
Immunoprecipitation 
CYP IA2 + - + - - - - + 
AADC + + + + + + + + 
Enzyme inhibition13 
CYP IA2 + NT + NT NT NT NT + 
aImmunofluorescence as described under Section 2. 
bIn % of control activity (without serum). 
+/— denotes presence or absence of the specified manifestation or reactivity. NT, not tested. 
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ing AADC [18] were used for in vitro transcription and translation 
using the TNT T7 and T3 coupled reticulocyte lysate system accord-
ing to the manufacturer's recommendation (Promega, Madison, WI). 
The [35S]methionine radiolabelled products were used for immunopre-
cipitation of patient sera as described below. 
2.6. Assay of antibodies against CYP IA2 and AADC 
[35S]Methionine radiolabelled CYP IA2 or AADC (5X105-1 X106 
cpm/well) and patient sera (dilution 1:10) were incubated overnight at 
4°C in buffer A, in a total volume of 50 ul, containing 150 mM NaCl, 
20 mM Tris-HCl, 0.02% NaN3, 0.1% (w/v) BSA and 0.15% (v/v) 
Tween-20, pH 8.0 (buffer A). The next day 50 ul of a 50% (v/v) slurry 
of protein A-sepharose (Pharmacia, Stockholm, Sweden) was added 
to each well of a microtitre plate (MABV N12, Millipore Corpora-
tion, Bedford, MA). The mixtures of sera and CYP IA2 or AADC 
respectively were then transferred to the wells, and the plate was 
shaken on a rotating platform for 45 min at 4°C. The plate was 
then washed using a vacuum manifold (Millipore) as follows: three 
washes with buffer A (200 ul in each well) followed by the addition of 
200 ul buffer A to each well and rotation on the platform for 5 min at 
4°C. This cycle was then repeated once, followed by two additional 
washes with 200 (xl of buffer A. Radioactivity was subsequently 
counted in a 1450 Micro Beta Trilux (Wallac, Turku, Finland). The 
results were expressed as a CYP IA2 or AADC index 
(cpmsampte- Cpm n e g a t j v e control/Cpmpositive control Cpmnegative control) * 10U0 
A CYP IA2 index of 400 and an AADC index of 200 were chosen as 
upper normal limits, dividing the cohort of APS I patients into those 
with elevated indices and those with normal and slightly elevated 
indices relative to the healthy controls (controlscYPiA2: —20 ±360 
and controlsAADC: 10 ± 70, mean ± 2 SD). Samples and controls 
were all analysed in duplicate. 
2.7. Enzyme inhibition studies 
Inhibition by patient sera of CYPlA2-specific 7-methoxyresorufin 
O-demethylase (MROD) activity was assayed using human liver mi-
crosomes from a non-smoking organ donor as the enzyme source 
[25,26]. Incubations contained 0.66 mg microsomal protein, 1.25 uM 
7-metnoxyresorufm dissolved in DMSO (Research Diagnostics Inc., 
NJ), 50 itM NADPH and 20 ul of serum in a total volume of 2 ml 
with 0.1 M sodium phosphate buffer pH 7.4. Prior to addition of 
NADPH, the assay mixture was incubated at 37°C for 5 min. The 
production of resorufin was followed by direct fluorimetry (k^ = 535 
nm, ^,m = 585 nm) on a Perkin-Elmar LS-5 Spectrofluorimeter, and 
the amount of resorufin produced was quantitated using the addition 
of a small amount of resorufin (Fluka) as an internal standard in each 
reaction mixture. 
3. Results 
3.1. Indirect immunofluorescence 
All eight APS I sera stained rat and human liver sections to 
various degrees with the indirect immunofluorescence method. 
The sera stained the cytoplasm of hepatocytes, predominantly 
those located perivenously (Fig. 1A). The same pattern was 
observed with a specific anti-CYP IA2 antiserum (Fig. IB). 
B H I 
• 84 kOa 
AADC 53,2 kDa 
■ 20,5 kDa 
Fig. 2. Western blot of a human liver cytosolic fraction, 30 ug of total protein/lane, with APS I patient and control sera. Patient sera were in-
cubated at a dilution of 1:100. Lane A: anti-AADC; lane B: anti-CYP IA2; lanes C-J: sera from APS I patients (#1, 6, 2, 7, 8, 3, 4 and 5, 
respectively); lane K: serum from a healthy control. Arrows to the right indicate the mobilities of prestained molecular weight standards. 
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Fig. 3. Western blot of a human liver microsomal fraction, 30 ug of total protein/lane, with APS I patient and control sera. Patient sera were 
incubated at a dilution of 1:100. Lane A: anti-CYP IA2; lanes B-I: sera from APS I patients (#1, 3, 8, 2, 4, 5, 6 and 7, respectively); lane J: 
serum from a healthy control. Arrows to the right indicate the mobilities of prestained molecular weight standards. 
Incubation with patient sera containing LKM1 autoantibod-
ies, as well with a specific rabbit antiserum against CYP IID6, 
resulted in homogeneous cytoplasmic staining of the whole 
liver lobule (not shown), clearly distinguishable from the pat-
tern obtained with anti-CYP IA2. Incubation with a specific 
antiserum against AADC yielded a very weak staining of a 
majority of liver cells, difficult to distinguish from the staining 
pattern obtained with control sera (data not shown), results in 
concordance with previous reports [24]. None of the 10 sera 
from healthy blood donors produced any liver staining (Fig. 
1C). 
3.2. Western blot analysis of liver fractions 
When the reactivities of the eight APS I sera against liver 
cytosol were analysed, it was found that seven of the eight 
sera reacted with an antigen with an apparent molecular 
weight (MW) of approximately 55 kDa corresponding in mo-
bility to AADC (Fig. 2). When the same analysis was per-
formed using liver microsomes, sera from the three patients 
with AI-CAH reacted with an antigen with the apparent MW 
of approximately 60 kDa co-migrating with that identified by 
specific CYP IA2 antisera (Fig. 3). Reactivity with a band 
corresponding to AADC was also seen in the microsomal 
fraction. A specific CYP IID6 antiserum (LKM1) identified 
a band in the microsomal fraction migrating with an apparent 
MW of 52 kDa clearly distinguishable from those identified 
by specific antibodies against CYP IA2, AADC and sera from 
APS I patients (not shown). No bands in the 50-60 kDa 
region were identified by sera from 10 healthy blood donors 
(Figs. 2 and 3) 
3.3. In vitro transcription and translation of CYP IA2 and 
AADC 
About 0.3% of the [35S]methionine became incorporated 
into the CYP IA2 protein. SDS-PAGE analysis of this protein 
yielded two bands with apparent MW of about 40 and 33 kDa 
respectively (not shown). Both bands were immunoprecipi-
tated by the specific rabbit anti-CYP IA2 antibody as well 
as by sera from APS I patients known to contain antibodies 
against CYP IA2. In the case of AADC, regularly about 
5% of the [35S]methionine became incorporated into the 
protein and SDS-PAGE analysis of this protein yielded a 
band corresponding to the full-length AADC molecule (not 
shown). 
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3.4. Autoantibodies against CYP IA2 and AADC analysed by 
immunoprecipitation of the in vitro translated proteins 
All eight sera contained autoantibodies against AADC, 
with an AADC index of above 200, while sera from the three 
patients with AI-CAH contained autoantibodies against CYP 
IA2, with a CYP IA2 index of above 400 (Fig. 4). No immu-
noreactivity against CYP IA2 or AADC was recognised by 
sera from 10 healthy blood donors (Fig. 4). 
3.5. Inhibition of CYP IA2 enzyme activity 
CYP IA2-mediated MROD activity [25,26] in human liver 
microsomes was inhibited to 40-50% by two of the three 
patient sera tested, and to 95% of control activity (no serum 
added) by the third patient serum. Normal sera from blood 
donors produced no inhibitory effects (Tables 1 and 2). 
4. Discussion 
Autoimmune hepatitis is the most feared component of 
APS I and, together with hypoparathyroidism and the con-
sequences of intestinal malabsorption, requires continuous 
monitoring. We demonstrate here that CYP IA2 and 
AADC are major autoantigens in liver tissue, and tests for 
the presence of autoantibodies against these antigens may 
have a role in the clinical evaluation of APS I patients. 
Subcellular fractions of liver homogenates were used to 
identify the autoantigens. In the cytoplasmic fraction, reactiv-
ity against a protein with mobility identical to that of AADC 
was found, and in the microsomal fraction, containing endo-
plasmic reticulum and the Golgi apparatus, a band with mo-
bility matching that of CYP IA2 was detected. In parallel, the 
reactivity of an LKM-1 standard serum was tested. This se-
rum displayed reactivity against a protein with a mobility that 
was different from that of both AADC and CYP IA2. Immu-
no-fluorescence staining of liver sections revealed a similar 
pattern for patient sera and anti-CYP IA2 sera, a pattern 
which was clearly different from that of LKM-1 antibodies, 
with a typical concentration of staining around central veins, 
where according to in situ hybridization studies CYP IA2 is 
located [10]. Radioligand assays based on in vitro transcribed/ 
translated proteins confirmed these results and provides an 
easy and reliable assay for AADC and CYP IA2 autoanti-
bodies. The in vitro transcription/translation product of CYP 
IA2 had a shorter length than expected, which implies that a 
small part of the protein is missing. A perfect correlation was 
obtained between the results of the radioligand and Western 
blot assays for both CYP IA2 and AADC. 
A 40-95% inhibition of the CYPlA2-specific 7-methoxyre-
Table 2 
CYP IA2 enzyme inhibition assay 
Activity" 
(pmol/min/mg protein) 
% Remaining activity 
Control15 
Patient 1 
Patient 3 
Patient 8 
Blood donor 1 
Blood donor 2 
12.2 
6.9 
0.6 
5.7 
12.2 
11.3 
100c 
57 
5 
47 
100 
93 
aCYP IA2-specific 7-methoxyresorufln O-demethylase activity as de-
scribed in Section 2. 
bIncubation mixture without serum as described in Section 2. 
c 100% = activity without serum added. 
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Fig. 4. Autoantibodies against CYP IA2 (a) and AADC (b) in APS 
I patients and controls measured as CYP IA2 and AADC indices. 
Immunoprecipitations and calculation of indices were performed as 
described in Section 2. The horizontal line indicates the upper nor-
mal limit, CYP IA2 index 400 (a) and AADC index 200 (b). 
sorufin O-demethylase (MROD) activity was observed with 
sera from the three patients suffering from AI-CAH, demon-
strating specific inhibitory effects of the CYP1A2 antibodies 
found in these sera. Due to a rather low specific activity of 
MROD in the human liver microsomes used as enzyme 
source, the amount of microsomal protein in each incubation 
was high, and therefore the serum/microsome ratio was lower 
than optimal. A stronger inhibitory effect would therefore 
have been anticipated if more patient serum was available 
for these analyses. This was reflected in a preparatory trial 
where increasing the amount of one of the sera from 10 to 
20 (il increased the inhibitory effect from 30 to 43%. 
Autoimmune chronic active hepatitis not associated with 
APS I is a poorly defined entity. Some forms of AI-CAH 
may represent a component of a systemic disease, e.g. sys-
temic lupus erythematosus (SLE) with anti-nuclear antibodies 
(ANA). Other forms of AI-CAH may represent viral diseases 
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for which no specific diagnostic tests are available, al though 
this possibility seems less likely today. The association of AI-
C A H with other autoimmune manifestations such as thyroi-
ditis and Sjogren's syndrome, and its association with HLA-
B8 [27], clearly suggest an underlying immune reaction. 
Cytochromes have previously been identified as autoanti-
gens in AI -CAH and other autoimmune endocrine disorders. 
In the uncommon type 2 autoimmune hepatitis, which mainly 
affects children, LKM-1 antibodies recognising CYP I ID6 [6] 
are found. Furthermore, in thienylic acid-induced hepatitis, 
antibodies against cytochrome P450 IIC9 [7] have been dem-
onstrated. In APS I, the cytochrome P450 cholesterol side-
chain cleavage enzyme (SCC) has previously been identified 
as an adrenal and gonadal autoantigen, and cytochrome P450 
21-hydroxylase is the major adrenal autoantigen in Addison's 
disease. On the basis of a previously reported case of AI -CAH 
with concomitantly decreased 25-hydroxylation of vitamin D 
in an APS I patient [28], we previously speculated that a 
vitamin D 25-hydroxylase could be a candidate as a hepatic 
autoantigen [14]. However, no results from experiments per-
formed as described in this report have corroborated this 
theory. 
In type 1 autoimmune hepatitis, A N A are found in about 
half of the patients. N o specific nuclear staining patterns are 
seen and the nuclear antigens have not been defined. Non-
organ-specific antibodies against smooth muscle and some-
times against mitochondria are also detected. In this larger 
group of A I - C A H patients, no specific diagnostic tests are 
available. It would be of interest to identify subgroups, per-
haps with different prognoses and treatment requirements, 
with more specific tests. 
In conclusion, measurements of CYP IA2 and A A D C anti-
bodies may be used bo th to monitor APS I patients with AI-
C A H and to identify those at risk of developing this disease. 
The value of C Y P IA2 or A A D C antibody testing in isolated 
AI -CAH remains to be elucidated. 
Acknowledgements: We wish to thank Anna-Carin Sundell and Maj-
stin Wik for excellent technical assistance and Professor A. Rane 
(Department of Clinical Pharmacology, University Hospital, Uppsala, 
Sweden) for the kind donation of anti-CYPIA2 and anti-CYP IID6 
antisera and Dr. Krieger (Laboratoire de Biochimie cellulaire, College 
de France, Paris, France) for providing anti-AADC antisera. This 
study was supported by grants from the Swedish Medical Research 
Council and from the Torsten and Ragnar Soderberg Fund, Bergwall 
Fund, Ake Wiberg Fund, Lars Johan Hierta Fund and Lennander 
fund. 
References 
[1] Neufeld, M.. 
9, 154-162. 
MacLaren, N. and Blizzard, R. (1980) Pediat. Ann. 
[19 
[20; 
[21 
[22 
[23; 
[24] 
[25 
[26] 
[27 
[28; 
Ahonen, P., Myllarniemi, S., Sipila, I. and Perheentupa, J. (1990) 
New Engl. J. Med. 322, 1829-1836. 
Husebye, E.S., Gebre-Medhin, G., Tuomi, T., Perheentupa, J., 
Landin-Olsson, M., Gustafsson, J., Rorsman, F. and Kampe, O. 
(1997) J. Clin. Endocrinol. Metab. 82, 147-150. 
Manns, M. (1989) J. Hepatol. 9, 272-280. 
Manns, M.P. (1991) Sem. Liver Dis. 11, 205-214. 
Zanger, U.M., Hauri, H.P., Loeper, J., Homberg, J.C. and 
Meyer, U.A. (1988) Proc. Natl. Acad. Sci. USA 27, 8256-8260. 
Beaune, P., Dansette, P.M. and Mansuy, D. et al. (1987) Proc. 
Natl. Acad. Sci. USA 84, 551-555. 
Sacher, M., Bllimel, P., Thaler, H. and Manns, M.J. (1990) Hep-
atology 10, 364-369. 
Manns, M.P., Griffin, K.J., Quattrochi, L.C., Sacher, M., Thaler, 
H., Tukey, R.H. and Johnson, E.R. (1990) Arch. Biochem. Bio-
phys. 280, 229-232. 
McKinnon, R.A., Hall, P.D.L.M., Quattrochi, L.C., Tukey, 
R.H. and McManus, M.E. (1991) Hepatology 14, 848-856. 
Distlerath, L.M., Reilly, P.E.B., Martin, M.V., Davis, G.G., Wil-
kinson, G.R. and Guengerich, F.P. (1985) J. Biol. Chem. 260, 
9057-9067. 
Butler, M.A., Iwasaki, M., Guengerich, F.P. and Kadlubar, F.F. 
(1989) Proc. Natl. Acad. Sci. USA 86, 7696-7700. 
Aaltonen, J., Bjorses, P., Sandkuijl, L., Perheentupa, J. and Pel-
tonen, L. (1994) Nature Genet. 8, 83-87. 
Winqvist, O., Gustafsson, J., Rorsman, F., Karlsson, F.A. and 
Kampe, O. (1993) J. Clin. Invest. 92, 2377-2385. 
Winqvist, O., Gebre-Medhin, G., Gustafsson, J., Ritzen, E.M., 
Lundkvist, 6. , Karlsson, F.A. and Kampe, O. (1993) J. Clin. 
Endocrinol. Metab. 80, 1717-1723. 
Velloso, L.A., Winqvist, O., Gustafsson, J., Kampe, O. and 
Karlsson, F.A. (1994) Diabetologia 37, 61-69. 
Tuomi, T., Bjorses, P., Falorni, A., Partanen, J., Perheentupa, J., 
Lernmark, A. and Miettinen, A. (1996) J. Clin. Endocrinol. 
Metab. 81, 1488-1494. 
Rorsman, F., Husebye, E.S., Winqvist, O., Bjork, E., Karlsson, 
F.A. and Kampe, O. (1995) Proc. Natl. Acad. Sci. USA 92, 
8626-8629. 
Christenson, J.G., Dairman, W. and Udenfriend, S. (1972) Proc. 
Natl. Acad. Sci. USA 69, 343-347. 
Rahman, M.K., Nagatsu, T. and Kato, T. (1981) Biochem. Phar-
macol. 30, 645-649. 
Winqvist, O., Karlsson, F.A. and Kampe, O. (1992) Lancet 339, 
1559-1562. 
Axen, E., Bergman, T. and Wikvall, K. (1992) Biochem. J. 287, 
725-731. 
Kampe, O., Andersson, A., Bjork, E., Hallberg, A. and Karlsson, 
F.A. (1989) Diabetes 38, 1326-1328. 
Jahng, J.W., Wessel, T.C., Houpt, T.A., Son, J.H. and Joh, T.H. 
(1996) J. Neurochem. 66, 14-19. 
Rodriguez, A.D. and Prough, R.A. (1992) Methods Enzymol. 
206, 423^131. 
Correia, M.A., in: P.R. Ortiz de Montellano (Ed.), Cytochrome 
P450. Structure, Mechanism, and Biochemistry Rat and Human 
Liver Cytochromes P450. Substrate and Inhibitor Specificities 
and Functional Markers, Plenum Press, New York, 1995, 
pp. 607-630. 
Morris, P.J., Vaughan, H., Tait, B.D. and Mackay, I.R. (1977) 
Aust. N.Z. J. Med. 7, 616. 
Gustafsson, J., Holmberg, I., Hardell, L.-I. and Foucard, T. 
(1984) Acta Endocrinol. 105, 211-214. 
